Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01042665 · ClinicalTrials.gov registry record
Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo
A clinical trial, sponsored by University of Miami.
- Completed
- Registry status
- 82
- Enrollment target
NCT01042665: Completed study, sponsored by University of Miami.
NCT01042665 is a clinical trial that has completed, run by University of Miami. The registered enrollment target is 82 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01042665 has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- 82 participants
- Enrollment target
Study Summary
The purpose of this investigation is to evaluate the relationship between IOP fluctuation, RGC dysfunction, and optic nerve and retinal nerve fiber layer (RNFL) thickness changes in patients with glaucoma and ocular hypertension receiving latanoprost 0.005% versus placebo.
Primary Outcome
RGC function is evaluated by pattern electroretinogram optimized for glaucoma (PERGLA)
Interventions
- DRUG Placebo
- DRUG latanoprost 0.005%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2006-02 |
| Est. Completion | 2009-12 |
What the finished NCT01042665 record still lists
NCT01042665 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 82 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01042665 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01042665 about?
NCT01042665 is a clinical study titled "Relationship Between Eye Pressure and Ganglion Cell Function in Eyes Receiving Latanoprost Versus Placebo". The purpose of this investigation is to evaluate the relationship between IOP fluctuation, RGC dysfunction, and optic nerve and retinal nerve fiber layer (RNFL) thickness changes in patients with glaucoma and ocular hypertension receiving latanoprost 0.005% versus placebo.
What is the current status of trial NCT01042665?
This trial is currently completed. The enrollment target is 82 participants. The study started on 2006-02. Estimated completion is 2009-12.
What interventions are being tested in trial NCT01042665?
The interventions under investigation include: Placebo (DRUG), latanoprost 0.005% (DRUG).
Who is sponsoring clinical trial NCT01042665?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03319901 · 82 participants · Phase 1
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
- NCT03493425 · 82 participants · Phase 2
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery
- NCT04105270 · 82 participants · Phase 2
RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial
- NCT04428658 · 82 participants · NA
Randomized Trial of Supplemental Synchronous and Asynchronous Telehealth to Improve Glycemic Control for Pediatric Patients With Type 1 Diabetes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia